Phase II trial of capecitabine and cisplatin in advanced, persistent, or recurrent carcinoma of the cervix

International Journal of Gynecological Cancer

Volumn 21, Issue 2, 2011, Pages 373-377

  Errihani, Hassan ^a   M'rabti, Hind ^a   Ismaili, Nabil ^a   Inrhaoun, Hanane ^a   Elghissassi, Ibrahim ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Morocco)

Author keywords

Capecitabine; Carcinoma; Cervix; Cisplatin

Indexed keywords

CAPECITABINE; CISPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DIARRHEA; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOSENSITIZATION; SEPSIS; TREATMENT DURATION; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CISPLATIN; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; UTERINE CERVICAL NEOPLASMS;

EID: 79956124813     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182094d9a     Document Type: Article

References (28)

1. Franco EL, Schlecht NF, Saslow D. The epidemiology of cervical cancer. Cancer. 2003;9:348-359. (Pubitemid 44403488)
2. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30. (Pubitemid 40310185)
3. Thigpen JT, Vance R, Puneky L, et al. Chemotherapy as a palliative treatment in carcinoma of the uterine cervix. Semin Oncol. 1995;22:16-24.
4. Thigpen JT, Shingleton H, Homesley H, et al. Cisplatinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix. A phase II study of the Gynecologic Oncology Group. Cancer. 1981;48:899-903. (Pubitemid 11049085)
5. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2004;22: 3113-3119. (Pubitemid 41103724)
6. Long HJ III, Bundy BN, Grendys EC Jr, et al. Randomized phase III trial of cisplatin (P) with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005;23:4626-4633. (Pubitemid 46224065)
7. Mutch DG, Bloss JD. Gemcitabine in cervical cancer. Gynecol Oncol. 2003;90:S8-S15.
8. Omura GA. Chemotherapy for stage IV B or recurrent cancer of the uterine cervix. Monogr Natl Cancer Inst. 1996;21: 123-126.
9. Kaern J, Trope C, Sundfoer K, et al. Cisplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up. Gynecol Oncol. 1996;60:387-392. (Pubitemid 26077622)
10. Budman DR, Meropol NJ, Reigner B, et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol. 1998;16:1795-1802.
11. MacKean MJ, Plantins AS, Twelves C, et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol. 1998;16:2977-2985. (Pubitemid 28417417)
12. Kang HJ, Chang HM, Kim TW, et al. Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy. Br J Cancer. 2005;92:246-251. (Pubitemid 40347314)
13. Kim TW, Chang HM, Kang HJ, et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol. 2003;14:1115-1120. (Pubitemid 36950177)
14. Ishikawa T, Utoh M, Sawada N, et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol. 1998;55:1091-1097. (Pubitemid 28167730)
15. Hindenburg AA, Matthews L. Complete and sustained remission of refractory cervical cancer following a single cycle of capecitabine. A case report. Int J Gynecol Cancer. 2003;13:898-900. (Pubitemid 38235238)
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
17. Garcia AA, Blessing JA, Darcy KM, et al. Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a Gynecologic Oncology Group study. Gynecol Oncol. 2007;104:572-579. (Pubitemid 46240236)
18. Jenkins AD, Ramondetta LM, Sun C, et al. Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix. Gynecol Oncol. 2005;97:840-844. (Pubitemid 40824655)
19. Look KY, Blessing JA, Michener CM, et al. Phase II evaluation of capecitabine in refractory nonsquamous cell carcinoma of he cervix: a Gynecologic Oncology Group study. Int J Gynecol Cancer. 2008;18:773-778. (Pubitemid 352020169)
20. Esaki T, Nakano S, Masumoto N, et al. Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line. Int J Gynecol Cancer Int J Cancer. 1996;65:479-484. (Pubitemid 26083256)
21. Teicher BA, Cucchi CA, Lee JB, et al. Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines. Cancer Res. 1986;46:4379-4383. (Pubitemid 16046857)
22. Miglietta L, Bruzzone M, Ghione G, et al. Chemotherapy with cisplatin and 5-fluorouracil chronomodulated infusion in locally advanced or metastatic/recurrent carcinoma of the cervix. Tumori. 2002;88:204-208. (Pubitemid 34875447)
23. Kaern J, Tropé C, Abeler V, et al. A phase II study of 5-fluorouracil/cisplatinum in recurrent cervical cancer. Acta Oncol. 1990;29:25-28. (Pubitemid 20084979)
24. Rotmensch J, Senekjian EK, Javaheri G, et al. Evaluation of bolus cis-platinum and continuous 5-fluorouracil infusion for metastatic and recurrent squamous cell carcinoma of the cervix. Gynecol Oncol. 1988;29:76-81.
25. Benjapibal M, Thirapakawong C, Leelaphatanadit C, et al. A pilot phase II study of capecitabine plus cisplatin in the treatment of recurrent carcinoma of the uterine cervix. Oncology. 2007;72:33-38. (Pubitemid 350249126)
26. Kaern J, Trope C, Kjorstad KE. A phase II study of 5-fluorouracil/ cisplatin in recurrent cervical cancer. Tidsskr Nor Laegeforen. 1990;110:2759-2762. (Pubitemid 20292062)
27. Zanetta G, Torri W, Bocciolone L, et al. Factors predicting response to chemotherapy and survival in patients with metastatic or recurrent. Squamous cell cervical carcinoma. A multivariate analysis. Gynecol Oncol. 1995;58:58-63.
28. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27: 4649-4655.